Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

15.96 -1.22 (-7.08%)
Streaming Delayed Price Updated: 1:20 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 6 Next >
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Clarifies Name, Ownership, and RTO Rumors Involving unbuzzd
Via Investor Brand Network
Topics Initial Public Offering
Quantum BioPharma Clarifies It Has Not Changed Its Name
From Quantum BioPharma
Via GlobeNewswire
What's Going On With Quantum Biopharma Stock Today?
Quantum Biopharma surges 15% after $2.35M settlement ends legal battle with ex-CEO Raza Bokhari. 
Via Benzinga
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
Via Investor Brand Network
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years 
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces Auditor Appointment and Name Change for Unbuzzd Wellness
Via Investor Brand Network
Topics Initial Public Offering
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives Australian Ethics Approval for Phase 2 Trial of FSD202 in MCAS Patients
Via Investor Brand Network
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Taps BitGo to Safeguard Crypto Assets
Via Investor Brand Network
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Signs Agreement to Advance MS Drug Toward Phase 2 Trial
Via Investor Brand Network
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma Stock Pops 20%, Retail Bullish Sentiment Builds After $1M Crypto Holdings Boost
The company increased its Bitcoin and cryptocurrency holdings to $4.5 million, reinforcing its strategy to hedge against currency fluctuations and improve shareholder value. 
Via Stocktwits
These stocks are moving in today's pre-market session
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Completes Dosing in Key Toxicity Studies for MS Drug Candidate
Via Investor Brand Network
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Files Amended $700M Market Manipulation Complaint in Federal Court
Via Investor Brand Network
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Anti-Corruption Advocate Kevin Malone as Board Advisor
Via Investor Brand Network
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Anti-Corruption Advocate Kevin Malone as Board Advisor
Via Investor Brand Network
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Issues Corporate Update
Via Investor Brand Network
Silver Linings Developing Underneath Market Surface; One New Swing Trade For Monday $SPY $QQQ
In this video lesson, I look at the overall market, what I expect the market to do in the intermediate term, my game plan per all my time frames and accounts. 
Via Talk Markets
Topics Stocks / Equities
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Prevails in Legal Dispute With Former CEO
Via Investor Brand Network
Topics Bonds
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due 
From Quantum BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.